Regulatory Approval Phase 3 Trials Regulatory Affairs FDA Approval Cancer Treatments Eli Lilly Phase 1 Trials Experimental Treatments Phase 2 Trials Oncology Combination Therapy Efficacy Studies Weight Loss Neurological Disorders Pharmacokinetics Preclinical Studies Antiviral Therapies Pilot Studies Pipeline Programs Patient Outcomes Phase I Trials Inhaled Insulin Trials Amivantamab Alzheimer's Treatments CagriSema Therapeutic Uses Patient-Derived Organoids Preclinical Testing Manufacturing Facilities Cancer Drugs GLP-1 Drugs Male Birth Control Combination Therapies Rejuvenation Medicine Antiviral Research Chemotherapy HypoxyStat Biomarkers Asthma Medications SARM1 Therapeutics Regulatory Approvals Repurposing Drugs India Rare Diseases Novo Nordisk Male Contraceptive Trials Ebola Treatments PMX205 Hormonal Research Preclinical Models Semaglutide Monoclonal Antibodies Neuropharmacology Human Health Safety Trials Research Institutions Ocrelizumab Inhibitors Hematology IRE1α Inhibitors Therapeutic Evaluation Precision Medicine Pre-clinical Studies Safety Testing RIPK1 Pathway
Want to see what podcasts are saying about this topic? Search across 135K+ podcasts. Explore Radar
The deal gives Lilly a precision antibody‑degradation platform and a Phase 1 candidate that cut disease‑driving antibodies, signaling a push to broaden its immunology pipeline.
